Coronavirus disease 2019 (COVID-19) was announced in early December 2019. The pandemic situation is declared. This study aimed to evaluate the role of biomarkers in estimating the severity and predicting the prognosis of COVID-19. A total of 116 confirmed patients were included in this study. The patients were evaluated clinically. The disease severity was assessed. The measured and calculated laboratory tests were done. The primary outcome is the 30-day mortality. Patients were assigned to the severe (14.7%) and non-severe (85.3%) groups. At IL-6 level of 32.3 pg/mL (the highest Youden’s index = 0.77), IL-6 can differentiate severe from non-severe patients with 82.4% sensitivity and 94.4% specificity. IL-6 can predict the severity [odds ratio of 87.7 (95% CI = 18.9-408.2) (P < 0.0001)]. After adjustment to the significant clinical and laboratory parameters, IL-6 had an adjusted odds ratio of 30.8 (95% CI = 1.1-728.3) (P = 0.046). A high CRP/albumin ratio of > 11.4 was associated with COVID-19 mortality [hazard ratio = 59.9 (95% CI = 7.4–488.3) (P < 0.0001)]. High CRP/albumin ratio had an adjusted hazard ratio of 26.5 (95% CI = 2.6-270.7) after adjustment of age and presence of co-morbidities (P = 0.006). IL-6 level could effectively discriminate COVID-19 severity. CRP/albumin ratio was an independent risk factor for 30-day mortality rate in patients with COVID-19. IL-6 and CRP/albumin ratio seem to be valuable biomarkers in evaluating the severity and prognosis of COVID-19, respectively.

中文翻译：

---

白细胞介素6和C反应蛋白/白蛋白比可预测COVID-19的严重程度和死亡率

2019年12月上旬宣布了2019年冠状病毒病（COVID-19）。疫情已经宣布。这项研究旨在评估生物标志物在估计严重程度和预测COVID-19预后中的作用。本研究共纳入116位确诊患者。对患者进行了临床评估。评估疾病的严重程度。完成了测量和计算的实验室测试。主要结果是30天死亡率。将患者分为严重组（14.7％）和非严重组（85.3％）。在IL-6水平为32.3 pg / mL（最高的尤登指数= 0.77）时，IL-6可以区分重度和非重度患者，敏感性为82.4％，特异性为94.4％。IL-6可以预测严重程度[比值比为87.7（95％CI = 18.9-408.2）（P <0.0001）]。在对重要的临床和实验室参数进行调整后，IL-6的调整比值比为30.8（95％CI = 1.1-728.3）（P = 0.046）。CRP /白蛋白比高> 11.4与COVID-19死亡率相关[危险比= 59.9（95％CI = 7.4-488.3）（P <0.0001）]。调整年龄和合并症后，高CRP /白蛋白比的调整后风险比为26.5（95％CI = 2.6-270.7）（P = 0.006）。IL-6水平可以有效地区分COVID-19严重程度。CRP /白蛋白比是COVID-19患者30天死亡率的独立危险因素。IL-6和CRP /白蛋白比似乎分别是评估COVID-19的严重程度和预后的有价值的生物标志物。4与COVID-19死亡率相关[危险比= 59.9（95％CI = 7.4-488.3）（P <0.0001）]。调整年龄和合并症后，高CRP /白蛋白比的调整后风险比为26.5（95％CI = 2.6-270.7）（P = 0.006）。IL-6水平可以有效地区分COVID-19严重程度。CRP /白蛋白比是COVID-19患者30天死亡率的独立危险因素。IL-6和CRP /白蛋白比似乎分别是评估COVID-19的严重程度和预后的有价值的生物标志物。4与COVID-19死亡率相关[危险比= 59.9（95％CI = 7.4-488.3）（P <0.0001）]。调整年龄和合并症后，高CRP /白蛋白比的调整后风险比为26.5（95％CI = 2.6-270.7）（P = 0.006）。IL-6水平可以有效地区分COVID-19严重程度。CRP /白蛋白比是COVID-19患者30天死亡率的独立危险因素。IL-6和CRP /白蛋白比似乎分别是评估COVID-19的严重程度和预后的有价值的生物标志物。CRP /白蛋白比是COVID-19患者30天死亡率的独立危险因素。IL-6和CRP /白蛋白比似乎分别是评估COVID-19的严重程度和预后的有价值的生物标志物。CRP /白蛋白比是COVID-19患者30天死亡率的独立危险因素。IL-6和CRP /白蛋白比似乎分别是评估COVID-19的严重程度和预后的有价值的生物标志物。